The AGMT\_COVID-19 Registry is designed as multicenter observational cohort of patients, that are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing to participate. Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified at the end of 2019 in Wuhan, the capital of Hubei province in central China, and has since spread globally. There are currently no authorised vaccines or treatments in the EU (European Union) to prevent or treat novel coronavirus disease (COVID-19) specifically or any other coronaviruses. The AGMT\_COVID-19 Registry is designed as multicenter observational cohort of patients, that are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing to participate. Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician.
Study Type
OBSERVATIONAL
Enrollment
1,000
LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)
Feldkirch, Austria
RECRUITINGKepler Universitätsklinikum Linz, Med. Campus III., Klinik für Lungenheilkunde / Pneumologie
Linz, Austria
RECRUITINGIIIrd Medical Department, Private Medical University Hospital Salzburg
Salzburg, Austria
Documentation of natural course and the therapeutic landscape of patients with COVID-19.
Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
KH Zams: Innere Medizin Internistische Onkologie und Hämatologie
Zams, Austria
RECRUITING